本帖最后由 老马 于 2013-3-13 13:43 编辑
; l, r3 P( O8 l; A$ s# o: Q2 B8 j2 S% z }6 \
健择（吉西他滨）+顺铂+阿瓦斯汀
! M$ P: S- |" A1 d Gemzar +Cisplatin + Avastin/ O. h5 s0 l( _6 `% s
http://annonc.oxfordjournals.org/content/21/9/1804.full; S( h& O2 Y) o4 g8 U6 q
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 N3 Y4 L9 t& gPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. * f2 p6 Q9 ~* F$ ]
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. - \1 K8 E- H1 D3 l7 G- `' f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
2 t8 B# K p; H! Y* Z' R华为网盘附件：
8 W7 y. \: i: k- u( z2 V【华为网盘】ava.JPG
3 l. C! v( X, w; [( b& a |
显身卡
